These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16917105)

  • 41. Renal effects of PPARalpha-agonists.
    Izzedine H; Launay-Vacher V; Baumelou A; Deray G
    Minerva Urol Nefrol; 2004 Dec; 56(4):339-42. PubMed ID: 15785426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pparα deficiency inhibits the proliferation of neuronal and glial precursors in the zebrafish central nervous system.
    Hsieh YC; Chiang MC; Huang YC; Yeh TH; Shih HY; Liu HF; Chen HY; Wang CP; Cheng YC
    Dev Dyn; 2018 Dec; 247(12):1264-1275. PubMed ID: 30358936
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of vascular smooth muscle cell proliferation: an indispensable target in treatment.
    Kardesoglu E; Yalcin M; Isilak Z; Uz O; Atalay M
    Chin Med J (Engl); 2012 Oct; 125(19):3600. PubMed ID: 23044337
    [No Abstract]   [Full Text] [Related]  

  • 44. Peroxisome Proliferator-Activated Receptor α Plays an Important Role in the Expression of Monocyte Chemoattractant Protein-1 and Neointimal Hyperplasia after Vascular Injury.
    Peng Y; Li Q; Zhang L; Bai M; Zhang Z
    PPAR Res; 2012; 2012():970525. PubMed ID: 22966226
    [TBL] [Abstract][Full Text] [Related]  

  • 45. To move or not to move? Cytochrome P450 products and cell migration.
    Fleming I
    Circ Res; 2002 May; 90(9):936-8. PubMed ID: 12016258
    [No Abstract]   [Full Text] [Related]  

  • 46. Stimulating effect of normal-dosing of fibrates on cell proliferation: word of warning.
    Cizkova K; Steigerova J; Gursky J; Ehrmann J
    Lipids Health Dis; 2016 Sep; 15(1):164. PubMed ID: 27658584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells.
    Cerbone A; Toaldo C; Pizzimenti S; Pettazzoni P; Dianzani C; Minelli R; Ciamporcero E; Roma G; Dianzani MU; Canaparo R; Ferretti C; Barrera G
    PPAR Res; 2012; 2012():269751. PubMed ID: 22619672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alpha 7 beta 1 integrin: putting the brakes on smooth muscle cell proliferation.
    Wilson E
    Circ Res; 2007 Sep; 101(7):651-3. PubMed ID: 17901369
    [No Abstract]   [Full Text] [Related]  

  • 49. Smooth muscle cell oligoclonality in vascular disease: same origin, different destinies.
    Matic L; Chemaly M; Hedin U
    Cardiovasc Res; 2023 May; 119(5):1100-1102. PubMed ID: 37011144
    [No Abstract]   [Full Text] [Related]  

  • 50. PPARα agonists--an emerging concept in the management of neuropathic and visceral pain.
    Kapoor S
    Psychopharmacology (Berl); 2012 Jun; 221(3):537-8. PubMed ID: 22461105
    [No Abstract]   [Full Text] [Related]  

  • 51. An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α.
    Sharma S; Sharma D; Dhobi M; Wang D; Tewari D
    Mol Cell Biochem; 2024 Mar; 479(3):707-732. PubMed ID: 37171724
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential Effects of sEH Inhibitors on the Proliferation and Migration of Vascular Smooth Muscle Cells.
    Kim HS; Kim SK; Kang KW
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232926
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model.
    Terry CM; Carlson ML; He Y; Ulu A; Morisseau C; Blumenthal DK; Hammock BD; Cheung AK
    J Vasc Res; 2014; 51(4):269-82. PubMed ID: 25196102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epoxides and soluble epoxide hydrolase in cardiovascular physiology.
    Imig JD
    Physiol Rev; 2012 Jan; 92(1):101-30. PubMed ID: 22298653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytochrome P450 eicosanoids and cerebral vascular function.
    Imig JD; Simpkins AN; Renic M; Harder DR
    Expert Rev Mol Med; 2011 Mar; 13():e7. PubMed ID: 21356152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Soluble epoxide hydrolase inhibition modulates vascular remodeling.
    Simpkins AN; Rudic RD; Roy S; Tsai HJ; Hammock BD; Imig JD
    Am J Physiol Heart Circ Physiol; 2010 Mar; 298(3):H795-806. PubMed ID: 20035028
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model.
    Liu JY; Yang J; Inceoglu B; Qiu H; Ulu A; Hwang SH; Chiamvimonvat N; Hammock BD
    Biochem Pharmacol; 2010 Mar; 79(6):880-7. PubMed ID: 19896470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.
    Simpkins AN; Rudic RD; Schreihofer DA; Roy S; Manhiani M; Tsai HJ; Hammock BD; Imig JD
    Am J Pathol; 2009 Jun; 174(6):2086-95. PubMed ID: 19435785
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic optimization of four soluble epoxide hydrolase inhibitors for use in a murine model of inflammation.
    Liu JY; Tsai HJ; Hwang SH; Jones PD; Morisseau C; Hammock BD
    Br J Pharmacol; 2009 Jan; 156(2):284-96. PubMed ID: 19154430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PPARs and the cardiovascular system.
    Hamblin M; Chang L; Fan Y; Zhang J; Chen YE
    Antioxid Redox Signal; 2009 Jun; 11(6):1415-52. PubMed ID: 19061437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.